↓ Skip to main content

Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation

Overview of attention for article published in Transplantation and Cellular Therapy, April 2018
Altmetric Badge

Mentioned by

twitter
5 X users

Citations

dimensions_citation
23 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation
Published in
Transplantation and Cellular Therapy, April 2018
DOI 10.1016/j.bbmt.2018.04.022
Pubmed ID
Authors

Alessandro Busca, Chiara Dellacasa, Luisa Giaccone, Sara Manetta, Lucia Biale, Laura Godio, Semra Aydin, Moreno Festuccia, Lucia Brunello, Benedetto Bruno

Abstract

Pure red cell aplasia (PRCS) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT). Many therapeutic options are available to treat this condition, including erythropoietin, rituximab, bortezomib, plasma exchange, immunoadsorption, donor lymphocyte infusion, mesenchymal stem cells, anti-thymocyte globulin and high-dose steroids; however treatment outcomes are often variable and can sometimes lead to disappointing results. In this brief article we report our experience with two patients with PRCA after major AB0-incompatible HSCT who were resistant to multiple therapeutic interventions and who eventually benefited from treatment with eltrombopag, a thrombopoietin mimetic approved by the Food and Drug Administration for the treatment of patients with immune thrombocytopenic purpura or severe aplastic anemia (SAA), refractory to immunosuppressive agents or not eligible to HSCT. Data from these two patients show that eltrombopag was effective in treating erythroid aplasia and transfusion dependence following HSCT in patients who did not benefit from multiple previous treatments. Moreover, eltrombopag was well tolerated, with only a transient thrombocytosis requiring dose adjustment, and no evidence of clonal evolution. Based on the positive results obtained in these two patients, we suggest that eltrombopag may have a favorable effect on unilineage cytopenias such as PRCA. Further studies in a large proportion of patients are mandatory to confirm these preliminary results.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 13%
Researcher 3 10%
Student > Doctoral Student 2 7%
Student > Master 2 7%
Student > Ph. D. Student 2 7%
Other 4 13%
Unknown 13 43%
Readers by discipline Count As %
Medicine and Dentistry 10 33%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Immunology and Microbiology 1 3%
Agricultural and Biological Sciences 1 3%
Other 2 7%
Unknown 14 47%